(Q46344899)

21 December 2017

title

Treatment of type 2 diabetes with incretin-based therapies (English)

1 reference

21 December 2017

0 references

1

1 reference

21 December 2017

language of work or name

English

0 references

publication date

24 September 2008

1 reference

21 December 2017

published in

The Lancet

1 reference

21 December 2017

volume

373

1 reference

21 December 2017

issue

9662

1 reference

21 December 2017

page(s)

438-439

1 reference

21 December 2017

The Physiology of Glucagon-like Peptide 1

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Glucagon-like peptide-1, glucose homeostasis and diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961247-7

7 January 2021

10.1016/S0140-6736(08)61247-7

Identifiers

DOI

1 reference

21 December 2017

1 reference

21 December 2017